Shoulder Innovations, Inc. (SI) vs ARS Pharmaceuticals, Inc. (SPRY)
A side-by-side comparison of Shoulder Innovations, Inc. and ARS Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
SI
Shoulder Innovations, Inc.
$19.59HealthcareDelayed quote: Oct 6, 2026, 2:15 PM EDT
SPRY
ARS Pharmaceuticals, Inc.
$4.28HealthcareDelayed quote: Oct 6, 2026, 2:25 PM EDT
Total return — SI vs SPRY
growth of $100 · dividends reinvested · last 1ySI +30.2% (+30.2%/yr)SPRY -76.0% (-76.0%/yr)SI compounded faster over this window
Log scale — wide-divergence pair
SI SPRY
SI vs SPRY: by the numbers
- •SPRY is the larger company ($425M vs $406M market cap).
- •Both run net losses; SI's is the smaller (-58.33% vs -184.24% net margin).
Metrics side by side
Valuation
| Metric | SI | SPRY |
|---|---|---|
| P/S ratio | 6.76 | 3.64 |
| P/B ratio | 3.27 | 33.98 |
Profitability
| Metric | SI | SPRY |
|---|---|---|
| Gross margin | 77.34% | 73.89% |
| Operating margin | -58.53% | -212.92% |
| Net margin | -58.33% | -184.24% |
| ROE | -28.18% | -1721.80% |
| ROIC | -25.26% | -114.65% |
Growth (annualized)
| Metric | SI | SPRY |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 36.43% |
| Total return CAGR (5Y) | N/A | -16.35% |
Go deeper
Dig into the metrics
Shoulder Innovations ROEARS Pharmaceuticals ROEShoulder Innovations operating marginARS Pharmaceuticals operating marginShoulder Innovations revenue growthARS Pharmaceuticals revenue growthShoulder Innovations free cash flowARS Pharmaceuticals free cash flow
Shoulder Innovations & ARS Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.